Targeted therapy before surgery for advanced skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two targeted drugs (an immunotherapy and an EGFR inhibitor) given before surgery to shrink locally advanced skin cancer and potentially make surgery easier or more successful. It may help people whose skin cancer is hard to treat with surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of skin cancer called cutaneous squamous cell carcinoma that is locally advanced—meaning it is hard to treat with surgery or has come back after previous treatments.
- You must not have received previous treatment with checkpoint inhibitors (like pembrolizumab or nivolumab) or EGFR inhibitors (like cetuximab) for your cancer.
- Your cancer must not have spread far from the original site, such as to other organs or distant lymph nodes.
- You need to have adequate kidney, liver, and bone marrow function, and be generally able to care for yourself (ECOG performance status 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.
Hear when a new Locally Advanced Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.